Neutralizing Power of Serum Antibodies - 2
Recruiting
N/A
Interventional Study
COVID-19
SARS-CoV-2 Viraemia
Monkey Pox
Vaccination
Serum
Mucosal Immunity
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Study type
- Interventional
- Purpose
- Basic Science
- Participants needed
- 30 (estimated)
- Sponsor
- Centre Hospitalier Régional d'Orléans · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
Severe forms of COVID-19 and Monkeypox affect immunocompromised and comorbid individuals. Vaccination and monoclonal antibody therapies induce neutralizing antibodies. This neutralizing power is recognized as a correlate of protection against a new infection. This study aims to describe the neutralizing power of serum and nasal antibodies over time, in relation to SARS-CoV-2 and MPXV vaccines or t…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Adults (≥18 years)
* Patients receiving or scheduled to receive anti-SARS-CoV-2 and/or anti-MPXV vaccines or monoclonal antibodies
* Patients have provided written informed consent
Exclusion Criteria:
* Persons under guardianship or curatorship
* Persons under legal protecti…
Contacts